EL7.AI
Mergers & AcquisitionsMediumUpdated•Originally published 25 June 2026•Updated 25 June 2026•
1 min read

New Developments in Merck-Bio-Techne Deal: Legal Probe, Downgrade, and Stock Surge 20%

Key Facts

1Purchase price of $73 per share in cash represents an enterprise value of $11.3 billion (EUR 9.9 billion)
2The premium is 36% to Bio-Techne's one-month volume weighted average trading price
3Merck KGaA expects annual cost synergies of approximately EUR 140 million to be fully realized by year 3 after closing

New developments have emerged in Merck KGaA's acquisition of Bio-Techne Corporation (NASDAQ:TECH). Law firm Halper Sadeh LLC has launched an investigation into the fairness of the $73.00 per share cash offer, signaling potential shareholder concerns. Meanwhile, Leerink Partners downgraded Bio-Techne stock to Market Perform from Outperform with a $73.00 price target, matching the offer price.

Bio-Techne shares surged 19.80% to $70.54 on volume of 38.38 million shares, representing a 24% premium over the prior Wednesday's closing price. The move follows the announcement of the $11.3 billion (€9.9 billion) enterprise value deal, which carries a 36% premium to the one-month VWAP. Merck expects annual cost synergies of approximately €140 million by year three after closing.

Merck KGaA (MKKGY) shares closed at $31.85 on June 24, while Bio-Techne shares now trade near the $73 offer price. The transaction is subject to customary regulatory approvals and is expected to close in the second half of 2026. Investors will monitor the legal investigation outcome, any competitor reactions, and further M&A activity in the life sciences sector.